P53, and its regulators, Mdm2, Mdm4, and Hausp, contain functional single nucleotide polymorphisms that attenuate the p53 pathway. Our study analyzes the role of four common polymorphisms in the p53 pathway, the P53 Arg72Pro (rs1042522), the Mdm2 SNP309 (rs2279744), the Mdm4 rs1380576 and the Hausp rs1529916, on the risk of developing aggressive prostate cancer. The results show that alleles in p53 gene regulators, Mdm2, Mdm4 and Hausp, instead of SNPs in p53 itself, are associated with either earlier age at diagnosis or more aggressive prostate cancer. These findings could point to the relevance of this pathway in the development of aggressive prostate cancer and lead to consideration of using these genetic variants as part of a multigenic model for identifying high-risk subgroups who may benefit from intensive therapeutic strategies. Results: We found that the Mdm2 SNP 309 T allele was associated with earlier onset prostate cancer (P = 0.004), higher Gleason scores (P = 0.004) and higher stages men undergoing a radical prostatectomy (RP) (P = 0.011). Both the Mdm4 and Hausp SNPs (rs1380576 and rs1529916) were found to be associated with higher D'Amico risk prostate cancer category at the time of diagnosis (P = 0.023 and P = 0.046, respectively).
Introduction
Tumor suppressor p53 lies at critical point of a complex signaling network for response to stress. The normal functioning p53 protein is involved in cell cycle arrest, DNA repair, apoptosis and maintenance of genetic integrity (1) . Therefore, it is regarded as a potent barrier to cancer. Malfunction of the p53 pathway is an almost universal hallmark of human tumors (2) . p53 is also found as one of the most commonly mutated genes in all types of human cancer. Mutations involving p53 are considered as late events during multi-step prostate carcinogenesis (3) . Apparently, loss of the wild-type p53 function can contribute to the hormone-resistance of prostate cancer cells (4) .
The Mdm2 oncoprotein is an established regulator of p53 via effects on p53 degradation and negative feedback inhibition (5) . The level of the Mdm2 protein in a cell or organism has a significant impact on cancer formation. Mdm2 can also reduce androgen receptor signaling in prostate cancer via p53 inhibition and is implicated in ubiquitination and degradation of androgen receptor by the Akt pathway (6) . Mdm2 protein is overexpressed in about 30-45% of analyzed prostate cancers (7, 8) . This over-expression was associated with advanced tumor stage or increased cell proliferation (7) .
Mdm4, which is a structural homolog of Mdm2, binds to the amino terminus of p53, functioning as a major inhibitor of p53 activity (9, 10) . Hausp (herpesvirus-associated ubiquitin-specific protease) stabilizes Mdm2, Mdm4, and p53 via its specific deubiquitinase activity (11) Arg, whereas the p53 Arg seems to induce apoptosis with faster kinetics and suppresses transformation more efficiently than the p53 Pro variant (12) . The relationship of p53
Arg72Pro with cancer susceptibility, reproduction and aging has been well-studied (13) (14) (15) (16) .
The pivotal role of Mdm2, Mdm4 and Hausp in the control of p53 function argues that polymorphisms at these loci may be important for the modulation of p53 function. A SNP (309 T > G) (rs2279744) in the promoter region of Mdm2, increases affinity for binding stimulatory protein (Sp) 1 leading to increased Mdm2 expression and the subsequent attenuation of the p53 pathway (17) . This SNP has been associated with susceptibility of certain types of cancer, including breast, lung, gastric and colon cancer (18) (19) (20) 
Materials and Methods

Study population
The details of the Dana-Farber Harvard Cancer Center SPORE (Gelb Center) Prostate
Cancer cohort have been previously described (31 To control the quality of the ethnicity information from the self-reported data, we 
Selection of SNPs
Two well-studied SNPs, p53 Arg72Pro (rs1042522) and Mdm2 SNP 309 (rs2279744), which have been shown to modify the activity or the levels of the p53 protein and influence cancer susceptibility, were chosen for this study (12, 17) . For Mdm4 gene, we chose to study SNP rs1380576, which is located in Mdm4 gene intron 1 region, and is in complete linkage disequilibrium (LD) (r 2 = 1) with a previously described SNP (rs2279744) which was reported under positive evolutionary selection and associated with risk of certain cancer (21, 22) .We also included the reported Hausp SNP (rs1529916), which is under evolutionary selection pressure and associated with human fertility in Caucasian (21).
DNA, SNPs and Genotyping assays
All DNA samples were extracted from peripheral whole blood using QIAamp DNA Blood mini kit (QIAGEN Inc, Valencia, CA). Genotyping was performed with Sequenom iPLEX matrix-assisted laser desorption/ionization-time of flight mass spectrometry technology. For quality control, about 5% random selected duplicates were included. No discrepancy between duplicates was observed in the genotyping data of all 4 SNPs. All
SNPs had greater than 99% genotype passing rates.
Research. pathway SNPs and RP Gleason Score or pathologic stages with unconditional logistic regression. The analyses, with the exception of those for early onset prostate cancer, were adjusted for age at diagnosis.
All statistical tests were performed using SAS version 9.1 (SAS Institute Inc, Cary, NC) and P < 0.05 (two-sided) was considered statistically significant. 
Results
Subject characteristics
Selected clinical characteristics of study participants are described in Table 1 
Correlation of SNPs with Age at diagnosis
We first estimate associations between the genotypes of p53 Arg72Pro, Mdm2 SNP 309, Mdm4 SNP (rs1380576) and Hausp SNP (rs152 9916) and the risk of developing an early onset prostate cancer ( 
Correlation of SNPs with D'Amico risk classification
In this analysis, we found that Mdm4 intron 1 SNP (rs1380576) was associated with D'Amico category (P = 0.023, 
Correlation of SNPs with RP Gleason score
In the patients who underwent RP, cases with RP Gleason score ≥ 7 were compared with RP Gleason score < 7 ( 
Correlation of SNPs with Pathologic stages
We also classified men as either having evidence of extraprostatic (T3/T4) or metastatic (N1 or M1) disease or localized disease (T1/T2) at prostatectomy. In this analysis ( 
Discussion
The p53 Arg72 Pro (rs1042522) polymorphism has been well characterized in both functional analyses and association studies (12) (13) (14) (15) (16) . In a limited number of studies in prostate cancer, no consistent conclusion has been made about the association between the p53 polymorphism and prostate cancer risk or clinicopathological variables (23) (24) (25) (26) 28) . This may be due to small sample sizes (< 200 prostate cancer cases) and/or mixed ethnic populations. In our present large homogeneous case-case analysis, we did not observe any statistically significant association between P53 Arg72 Pro polymorphism and prostate cancer aggressiveness or pathologic variables.
The Mdm2 SNP309 T > G (rs2279744) is a functional SNP that increases Mdm2
expression levels and attenuates the p53 pathway (17) . Only a few studies have addressed an association of Mdm2 SNP 309 with prostate cancer in relatively small cohorts (27) (28) (29) (30) .
Intriguingly, previous studies have implicated that G allele of Mdm2 SNP 309 was the high-risk allele in many other kinds of carcinoma (17, 19, 20) . Our current study found that the T allele was associated with earlier onset prostate cancer (≤ 60 yrs) in the entire cohort, higher RP Gleason (≥ 7) and advanced pathologic stages in RP patients. Our data is not the first to note that the T allele is associated with an increase risk or aggressiveness of prostate cancer. Kibel et al (29) examined the Mdm2 SNP309 polymorphism in a European-American cohort of 186 patients with advanced prostate cancer and 220 cancer-free controls and found that the T allele of Mdm2 SNP 309 was associated with an increased risk of advanced prostate cancer. In addition, studies from
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